KINGSTON, Jamaica – Jamaica's government says it awarded 61 contracts, valued at J$27 billion (One Jamaica dollar=US$0.008 cents) for the procurement of essential drugs under the 2023-2026 pharmaceutical awards program.
Health and Wellness Minister, Dr. Christopher TuftonHealth and Wellness Minister, Dr. Christopher Tufton, speaking at a ceremony where the contracts were signed between the National Health Fund (NHD) and 34 local and international suppliers, said the investment is significant and will benefit over 700,000 Jamaicans.
LASCO Distributors Ltd. was awarded the largest contract at J$3.86 billion, followed by Cari-Med Group and Facey Commodity Ltd. with J$3.69 billion and J$3.52 billion, respectively.
The pharmaceuticals to be supplied under the contracts are those on the Ministry’s list of Vital Essential and Necessary (VEN) drugs and will be distributed to hospitals, health centers and 106 Drug Serv Pharmacies island-wide.
Tufton said with the government spending billions of dollars annually to treat non-communicable diseases (NCDs), Jamaica’s sick profile is growing, and something has to be done to address the situation.
“It is a challenge and trajectory that becomes very difficult to sustain overtime without some changes…Jamaicans must appreciate that the government is making its best effort to respond to their concerns, but they must also appreciate that they have a responsibility to help in ensuring their own personal wellness and collectively, the wellness of the society,” he said.
NHF board member, Cecile Watson, said the Fund is a critical organization in Jamaica’s healthcare system.
“The absence of accessible medication can cast a shadow over Jamaica’s Human Development Index, particularly the component that speaks directly to the pursuit of a prolonged and robust life. The implications of any prolonged medication shortage on our society’s overall health and well-being cannot be overstated,” she said.
She urged suppliers to enhance supply chain resilience, which will ensure a consistent and reliable flow of medications, even in times of international upheaval.
“We ask that you recognize the socio-economic impact of accessible healthcare and continue to offer favorable pricing and terms for essential medications. By doing so, we are taking strides towards reducing the burden on our healthcare system and enabling more equitable access to life-saving treatments,” she said.
